Prostate Cancer Report
ASCO GU 2019

The Prostate Cancer market was impacted by nmCRPC¹, mCSPC² and mCRPC³ data presented during the ASCO Genitourinary Cancers Symposium (ASCO-GU) meeting in San Francisco, CA.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for ZYTIGA^® (abiraterone), ERLEADA^® (apalutamide), XTANDI^® (enzalutamide), LYNPARZA^® (olaparib) + KEYTRUDA^® (pembrolizumab), YERVOY^® (ipilimumab) + OPDIVO^® (nivolumab), ZEJULA^®, (niraparib) and darolutamide.

Companies presenting data included: AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Pfizer.

Get immediate access to this 54-slide report so you can make better decisions today and prepare for tomorrow.